Microsoft delves into biomarkers
eWeek | at | by Mike
The cross-industry group Microsoft formed last spring to better integrate technology into the process of drug development has announced its second research venturea project intended to simplify the process for identifying and validating genomic biomarkers, which often indicate the likelihood of disease or drug efficacy.
The BioIT Alliance's first project, a "collaborative molecular environment" in which researchers can share data visualization and annotation tools, is well under way with The Scripps Research Institute.
"One of the most important fields of research today is in gaining an understanding of the relationship between genetic traits and clinical outcomes," said Dr. Michael Hanley, vice president of discovery research at Amylin Pharmaceuticals.